scholarly journals The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A

1991 ◽  
Vol 266 (3) ◽  
pp. 1879-1887 ◽  
Author(s):  
E M Meier ◽  
G Schwarzmann ◽  
W Fürst ◽  
K Sandhoff
2021 ◽  
Author(s):  
Warren W. Wakarchuk ◽  
Incilay Sinici ◽  
Sayuri Yonekawa ◽  
Ilona Tkachyova ◽  
Steven J. Gray ◽  
...  

The hydrolysis in lysosomes of GM2 ganglioside to GM3 ganglioside requires the correct synthesis, intracellular assembly and transport of three separate gene products; i.e., the alpha and beta subunits of heterodimeric beta-hexosaminidase A, E.C. # 3.2.1.52 (encoded by the HEXA and HEXB genes, respectively), and the GM2-activator protein (GM2AP, encoded by the GM2A gene). Mutations in any one of these genes can result in one of three neurodegenerative diseases collectively known as GM2 gangliosidosis (HEXA, Tay-Sachs disease, MIM # 272800; HEXB, Sandhoff disease, MIM # 268800; and GM2A, AB-variant form, MIM # 272750). Elements of both of the hexosaminidase A subunits are needed to productively interact with the GM2 ganglioside-GM2AP complex in the lysosome. Some of these elements have been predicted from the crystal structures of hexosaminidase and the activator. Recently a hybrid of the two subunits has been constructed and reported to be capable of forming homodimers that can perform this reaction in vivo, which could greatly simplify vector-mediated gene transfer approaches for Tay-Sachs or Sandhoff diseases. A cDNA encoding a hybrid hexosaminidase subunit capable of dimerizing and hydrolyzing GM2 ganglioside could be incorporated into a single vector, whereas packaging both subunits of hexosaminidase A into vectors, such as adeno-associated virus, would be impractical due to size constraints. In this report we examine the previously published hybrid construct (H1) and a new more extensive hybrid (H2), with our documented in cellulo (live cell- based) assay utilizing a fluorescent GM2 ganglioside derivative. Unfortunately when Tay-Sachs cells were transfected with either the H1 or H2 hybrid construct and then were fed the GM2 derivative, no significant increase in its turnover was detected. In vitro assays with the isolated H1 or H2 homodimers confirmed that neither was capable of human GM2AP-dependent hydrolysis of GM2 ganglioside.


2004 ◽  
Vol 324 (3) ◽  
pp. 1048-1052 ◽  
Author(s):  
Maryam Zarghooni ◽  
Scott Bukovac ◽  
Michael Tropak ◽  
John Callahan ◽  
Don Mahuran

1999 ◽  
Vol 258 (2) ◽  
pp. 256-259 ◽  
Author(s):  
Brigitte Rigat ◽  
Denis Reynaud ◽  
Natasha Smiljanic-Georgijev ◽  
Don Mahuran

2015 ◽  
Vol 10 (1) ◽  
pp. 102-109 ◽  
Author(s):  
Laddawan Potprommanee ◽  
Haou-Tzong Ma ◽  
Lalida Shank ◽  
Yi-Hsiu Juan ◽  
Wei-Yu Liao ◽  
...  

1999 ◽  
Vol 10 (3) ◽  
pp. 435-443
Author(s):  
THOMAS M. MUNDEL ◽  
HANS W. HEID ◽  
DON J. MAHURAN ◽  
WILHELM KRIZ ◽  
PETER MUNDEL

Abstract. This study describes the molecular characterization of an antigen defined by an autoantibody from a woman with habitual abortion as GM2-activator protein. The patient showed no disorder of renal function. Accidentally with routine serum screening for autoantibodies, an immunoreactivity was found in kidney collecting duct intercalated cells. Three distinct patterns of immunostaining of intercalated cells were observed: staining of the apical pole, basolateral pole, and diffuse cytoplasmic labeling. Ultrastructurally, the immunoreactivity was associated with “studs,” which represent the cytoplasmic domain of the vacuolar proton pump in intercalated cells. This pump is subjected to a shuttling mechanism from cytoplasmic stores to the cell membrane, which exclusively occurs in intercalated cells. Peptide sequences of a 23-kD protein purified from rat kidney cortex showed complete identity with corresponding sequences of GM2-activator protein. In the brain, GM2-activator protein is required for hexosaminidase A to split a sugar from ganglioside GM2. Because neither ganglioside GM2 nor GM1 (its precursor) is present in significant amounts in the kidney, the previous finding that this tissue contains the highest level of activator protein in the body was confusing. In this study, a novel role for GM2-activator protein in intercalated cells is proposed, and possible roles in the shuttling mechanism are discussed.


PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e57908 ◽  
Author(s):  
Incilay Sinici ◽  
Sayuri Yonekawa ◽  
Ilona Tkachyova ◽  
Steven J. Gray ◽  
R. Jude Samulski ◽  
...  

2021 ◽  
Author(s):  
Warren W. Wakarchuk ◽  
Incilay Sinici ◽  
Sayuri Yonekawa ◽  
Ilona Tkachyova ◽  
Steven J. Gray ◽  
...  

The hydrolysis in lysosomes of GM2 ganglioside to GM3 ganglioside requires the correct synthesis, intracellular assembly and transport of three separate gene products; i.e., the alpha and beta subunits of heterodimeric beta-hexosaminidase A, E.C. # 3.2.1.52 (encoded by the HEXA and HEXB genes, respectively), and the GM2-activator protein (GM2AP, encoded by the GM2A gene). Mutations in any one of these genes can result in one of three neurodegenerative diseases collectively known as GM2 gangliosidosis (HEXA, Tay-Sachs disease, MIM # 272800; HEXB, Sandhoff disease, MIM # 268800; and GM2A, AB-variant form, MIM # 272750). Elements of both of the hexosaminidase A subunits are needed to productively interact with the GM2 ganglioside-GM2AP complex in the lysosome. Some of these elements have been predicted from the crystal structures of hexosaminidase and the activator. Recently a hybrid of the two subunits has been constructed and reported to be capable of forming homodimers that can perform this reaction in vivo, which could greatly simplify vector-mediated gene transfer approaches for Tay-Sachs or Sandhoff diseases. A cDNA encoding a hybrid hexosaminidase subunit capable of dimerizing and hydrolyzing GM2 ganglioside could be incorporated into a single vector, whereas packaging both subunits of hexosaminidase A into vectors, such as adeno-associated virus, would be impractical due to size constraints. In this report we examine the previously published hybrid construct (H1) and a new more extensive hybrid (H2), with our documented in cellulo (live cell- based) assay utilizing a fluorescent GM2 ganglioside derivative. Unfortunately when Tay-Sachs cells were transfected with either the H1 or H2 hybrid construct and then were fed the GM2 derivative, no significant increase in its turnover was detected. In vitro assays with the isolated H1 or H2 homodimers confirmed that neither was capable of human GM2AP-dependent hydrolysis of GM2 ganglioside.


Sign in / Sign up

Export Citation Format

Share Document